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Regulatory T cells (Tregs) are critical for maintaining
immune homeostasis, but their presence in tumor
tissues impairs anti-tumor immunity and portends
poor prognoses in cancer patients. Here, we reveal
a mechanism to selectively target and reprogram
the function of tumor-infiltrating Tregs (TI-Tregs) by
exploiting their dependency on the histone H3K27
methyltransferase enhancer of zeste homolog 2
(EZH2) in tumors. Disruption of EZH2 activity in
Tregs, either pharmacologically or genetically, drove
the acquisition of pro-inflammatory functions in
TI-Tregs, remodeling the tumor microenvironment
and enhancing the recruitment and function of
CD8+ and CD4+ effector T cells that eliminate tumors.
Moreover, abolishing EZH2 function in Tregs was
mechanistically distinct from, more potent than,
and less toxic than a generalized Treg depletion
approach. This study reveals a strategy to target
Tregs in cancer that mitigates autoimmunity by re-
programming their function in tumors to enhance
anti-cancer immunity.
INTRODUCTION
Regulatory T cells (Tregs) are an immunosuppressive subset of
CD4+ T cells that are essential for maintaining immune tolerance
and preventing autoimmune disease. Defects in the Treg master
regulatory transcription factor FOXP3, or Treg depletion, leads to
rapid lymphoproliferation and the onset of multi-organ autoim-3262 Cell Reports 23, 3262–3274, June 12, 2018 ª 2018 The Authors
This is an open access article under the CC BY-NC-ND license (http://munity in both humans and mice (Sakaguchi et al., 2008). While
critical for controlling inappropriate immune responses to self,
Tregs have been found at extremely high frequencies in nearly
all cancers (Curiel et al., 2004; Saito et al., 2016). It is hypothe-
sized that cancers have co-opted this natural mechanism of
immune tolerance to blunt anti-tumor immune responses
because the presence of Tregs in tumor tissues is commonly
associated with poorer prognoses (Curiel et al., 2004; Liu et al.,
2016a; Saito et al., 2016; Schreiber et al., 2011). Therefore, tar-
geting Tregs may provide a powerful means to unleash more
potent immune responses against cancer.
Generalized depletion of Tregs in murine cancer models by
treatment with antibodies against the high-affinity interleukin-2
(IL-2) receptor (CD25) or genetic ablation approaches have
been shown to slow the progression or even lead to the rejec-
tion of several types of cancer (Bos et al., 2013; Klages et al.,
2010; Shimizu et al., 1999; Teng et al., 2010a, 2010b). However,
these strategies must be limited in duration because the gener-
alized inactivation of Tregs incites severe systemic autoimmune
toxicities (Joshi et al., 2015; Liu et al., 2016b). For these strate-
gies to be most effective, methods to selectively target intratu-
moral Tregs are needed that preserve Tregs at other locations in
the body to prevent autoimmune reactions. Preferential ablation
of intratumoral Tregs has been achieved in some instances,
such as with depleting anti-CTLA-4 or anti-CCR4 antibody
treatments (Selby et al., 2013; Simpson et al., 2013; Sugiyama
et al., 2013), which has led to strong anti-tumor responses
with reduced autoimmune toxicities. This supports the hypoth-
esis that directly targeting the function of Tregs in tumor tissues
is most efficacious. Alternatively, investigations have shown
that the immunosuppressive phenotype of Tregs is vulnerable,
and in the context of inflammatory environments, Tregs are
reprogrammed to become pathogenic T cells with effector.
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functions (Bailey-Bucktrout et al., 2013; Oldenhove et al., 2009;
Zhou et al., 2009). In the setting of cancer, blocking the engage-
ment of ligands with several critical receptors on Tregs, such as
CD25, glucocorticoid-induced tumor necrosis factor (TNF) re-
ceptor (GITR), or neuropilin-1 (Nrp-1), has demonstrated that
the immunosuppressive properties of Tregs can be replaced
by pro-inflammatory activities that beneficially augment im-
mune responses to cancers (Nakagawa et al., 2016; Overa-
cre-Delgoffe et al., 2017; Rech et al., 2012; Schaer et al.,
2013). Targeting the functional plasticity of immune cells repre-
sents a powerful new mechanism to promote immune re-
sponses to cancer because it can both subvert immune toler-
ance, by removing immunosuppressive cells from tumors, and
directly boost anti-tumor immunity, by converting the Treg
niche from immunosuppressive to immunostimulatory (DuPage
and Bluestone, 2016).
The development of targeted small molecule anti-cancer
agents designed to directly affect critical pathways in tumor cells
has brought about new opportunities for targeting intracellular
pathways that control immune plasticity. By determining how
these agents impinge on immune cells or other accessory cells
of the tumor microenvironment, it may be possible to repurpose
these drugs to simultaneously alter key immune cell populations
to complement immunotherapeutic treatments for cancer. Small
molecule inhibitors of enhancer of zeste homolog 2 (EZH2) are
being evaluated in clinical trials as direct anti-cancer agents,
but their potential to disrupt regulatory immune cells to promote
tumor immunity remains unexplored (Kim andRoberts, 2016; Tif-
fen et al., 2016). EZH2, a histone H3K27methyltransferase of the
polycomb repressor complex 2 (PRC2) that controls chromatin
condensation, is induced upon Treg activation, functioning as
an epigenetic switch necessary to maintain Treg stability and
function in tissues (Arvey et al., 2014; DuPage et al., 2015).
Previous studies have shown that the disruption of EZH2 in Tregs
selectively altered the stability of FOXP3 expression in activated
Tregs and led to the acquisition of pro-inflammatory properties in
these cells (DuPage et al., 2015; Sarmento et al., 2017; Zhang
et al., 2014). Here, we investigated the importance of EZH2 in
regulating immune function within the tumor microenvironment
and shaping anti-tumor immunity.
RESULTS
T Cell-Dependent Anti-cancer Activity of
Pharmacological EZH2 Inhibitors
To investigate whether EZH2 inhibition in immune cells modu-
lates cancer progression, we administered an EZH2 inhibitor
(CPI-1205, Constellation Pharmaceuticals [Vaswani et al.,
2016]) to mice transplanted with a murine colorectal tumor
(MC38). The MC38 tumor model was chosen because EZH2
did not exhibit intrinsic oncogenic properties, as treatment of
cells in vitro did not affect cell proliferation despite a clear
reduction in the levels of H3K27me3 in cells (Figures S1A–
S1C). Furthermore, treatment of mice with an EZH2 inhibitor
did not slow MC38 tumor growth when transplanted into
T cell-deficient Rag-1/mice. In fact, tumor growth was accel-
erated in this immunodeficient setting (Figure 1A). In sharp
contrast, treatment of tumor-bearing immunocompetent micewith the EZH2 inhibitor led to dramatic inhibition of tumor pro-
gression, indicating a tumor cell extrinsic mechanism for
EZH2 inhibition that involved adaptive immune cells (Figure 1B).
Indeed, mice receiving an EZH2 inhibitor had enhanced propor-
tions of CD8+ T cells in tumors, implicating an augmented
effector T cell response for improving tumor control (Figure 1C).
Recent studies have shown that the blockade of EZH2 function
within tumor cells increased their expression of chemokines
that enhanced the anti-tumor immune response (Nagarsheth
et al., 2016; Peng et al., 2015; Zingg et al., 2017), but EZH2
inhibition of MC38 cells grown in vitro did not increase the
expression or secretion of CXCL9 or CXCL10 (Figures S1D
and S1E). Importantly, the contribution of EZH2 activity within
tumor-infiltrating Tregs (TI-Tregs) has not been explored. There-
fore, we assessed Tregs from tumor-bearing mice treated with
the EZH2 inhibitor. Tregs retained normal levels of EZH2 protein
expression, but they had significantly reduced levels of
H3K27me3 resulting from the inhibition of the enzymatic activity
of EZH2 in Tregs (Figure 1D). While EZH2 inhibition did not
reduce the frequency of Tregs in tumors, the ratio of CD8+
T cells to Tregs was increased in tumors (Figures 1E and 1F).
Most significant, pharmacologic blockade of EZH2 led to
reduced levels of FOXP3 protein in Tregs (Figure 1G), which is
in line with the results of studies in which Ezh2 was genetically
disrupted in Tregs (DuPage et al., 2015). These data reveal a
critical role for T cells in mediating the anti-cancer effects of
EZH2 inhibitor treatment and implicate Tregs as a potential
target of EZH2 inhibition.
Increased EZH2 Activity in Tregs Infiltrating Murine and
Human Cancers
To determine whether TI-Tregs are sensitive to EZH2 inhibition
because of increased expression of the protein, we compared
the level of EZH2 expression and activity in T cells from different
tissues of MC38 tumor-bearing mice. EZH2 protein and its
histone modification (H3K27me3) were increased in Tregs
compared to effector CD4+Foxp3 T cells (Teff) in tumors, but
not when comparing the T cells from tumor-draining lymph no-
des (dLNs) (Figures 2A and S1F). In addition, Tregs exhibited a
clear induction of EZH2 and H3K27me3 levels specifically within
tumor tissues as compared to other non-lymphoid tissue
(Figure 2B).
Examination of human Tregs infiltrating melanomas re-
vealed a similar pattern of EZH2 induction in TI-Tregs. Within
patient tumors, Tregs (CD4+FOXP3+) expressed higher levels
of EZH2 protein compared to Teff (CD4+Foxp3CD25)
despite equivalent activation states (both CD44+), but
increased levels of EZH2 were not observed in Tregs from
the peripheral blood (Figures 2C and S1G). Gene expression
analysis of T cells from human colorectal cancer (CRC),
non-small cell lung cancer (NSCLC), and breast cancers (De
Simone et al., 2016; Plitas et al., 2016) also revealed an induc-
tion of EZH2 transcript levels in TI-Tregs compared to TI-Teff
or in TI-Tregs compared to normal tissue-resident Tregs (Fig-
ures 2D and 2E). Taken together, these data support a
hypothesis whereby TI-Tregs have enhanced EZH2 activity
that when disrupted may impair their capacity to inhibit
T cell responses to cancer.Cell Reports 23, 3262–3274, June 12, 2018 3263
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Figure 1. EZH2 Inhibition Disrupts Tumor Progression via a T Cell-Dependent Mechanism
(A and B) Growth curve of MC38 tumors in untreated or EZH2 inhibitor-treated Rag-1/ mice (A) or C57BL/6 mice (B) beginning 1 day after tumor inoculation
throughout the experiment. Inset numbers represent the number of mice that rejected tumors of total implanted.
(C) Percentage of CD8+ T cells of viable CD45+ immune cells in MC38 tumors in (B) by flow cytometric analysis.
(D) Mean fluorescent intensity (MFI) of antibody staining for H3K27me3 and EZH2 in Tregs from untreated or EZH2 inhibitor-treated mice from (B).
(E and F) Percentage of FOXP3+ Treg cells of CD4+ T cells (E) and ratio of CD8+ T cell to FOXP3+ Tregs (F) in tumors from (B).
(G) MFI of antibody staining for FOXP3 in Tregs from untreated or EZH2 inhibitor-treated mice from (B).
Data represent means ± SEMs; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 from two-way ANOVA with Sidak’s multiple comparisons or by unpaired
t tests. See also Figure S1.Potent Anti-cancer Immunity in Mice with Targeted
Disruption of Ezh2 in Tregs
To dissect the role of EZH2 activity specifically in Tregs, we
transplanted tumors into mice genetically engineered to delete
Ezh2 constitutively in Tregs (Foxp3-GFP-Cre;Ezh2fl/fl, abbrevi-
ated FP3;Ezh2fl/fl). Compared to littermate controls (FP3;Ezh2fl/+
or Ezh2fl/[fl/+]), FP3;Ezh2fl/flmice completely rejected colon carci-
nomas (MC38) and prostate carcinomas (TRAMPC2) after an
early tumor growth phase (Figures 3A, 3B, and S2A). In the
context of a poorly immunogenic model of melanoma
(B16F10), tumor growth was reduced significantly (Figure 3C).
While in this setting tumors were not rejected, a prior vaccination
regimen with irradiated granulocyte macrophage-colony-stimu-
lating factor (GM-CSF)-expressing B16F10 cells (B16-GVAX) led
to the rejection of melanomas in FP3;Ezh2fl/fl but not FP3;Ezh2fl/+
mice (Figure 3C). Similarly, treatment of wild-type mice with a
combination of an EZH2 inhibitor and the B16-GVAX vaccination
led to the rejection of B16F10 tumors (Figure S2B), supporting a
hypothesis that EZH2 inhibition can synergize with cancer immu-
notherapeutic modalities.
To more broadly investigate the capacity of H3K27me3 levels
in Tregs to alter anti-cancer immune responses, we examined
the growth of MC38 tumors in mice with a Treg-specific defi-
ciency for the H3K27 demethylase JMJD3, which opposes
EZH2 function by removing methylation marks from H3K273264 Cell Reports 23, 3262–3274, June 12, 2018(FP3;Jmjd3fl/fl versus FP3;Jmjd3fl/+ littermates). In these mice,
loss of JMJD3 in Tregs leads to increased levels of H3K27me3,
and consequently FP3;Jmjd3fl/fl mice exhibited a more rapid
outgrowth of MC38 tumors (Figure 2D). These results support
the hypothesis that control of the level of H3K27me3 by EZH2
in Tregs is crucial for their capacity to suppress anti-tumor
immune responses.
Ezh2 Disruption in Tregs Enhances the Number and
Function of Tumor-Infiltrating T Cells
To understand how Ezh2 deficiency in Tregs enhanced the im-
mune response against tumors, we analyzed the composition
of tumor-infiltrating lymphocytes by immunohistochemistry and
flow cytometry. This revealed that FP3;Ezh2fl/fl mice harbored
significantly increased numbers and proportions of CD8+ and
eCD4+ (CD4+Foxp3) T cells within their tumors, similar to
what we observed in the tumors of mice treated with an EZH2
inhibitor (Figures 4A–4D, S2C, and S2D). We also investigated
the functionality of tumor-infiltrating T cells by restimulation
in vitro and staining for intracellular cytokine production by
flow cytometry. In FP3;Ezh2fl/fl mice, the polyfunctionality of tu-
mor-infiltrating T cells was markedly enhanced, with CD8+ and
eCD4+ T cells capable of co-producing multiple cytokines,
including interferon-g (IFN-g), TNF-a, and IL-2 (Figures 4E–4G).
Both CD8+ and CD4+ T cells were required for tumor clearance
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Figure 2. Elevated Expression of EZH2 in Tumor-Infiltrating Tregs
(A) Flow cytometric staining for EZH2 and H3K27me3 levels in Teff (filled histogram) and Treg (solid black line) cells isolated from mouse MC38 tumors (top) and
tumor draining lymph nodes (bottom). Quantification of data from two independent experiments with two to three mice per group is shown with Treg MFI relative
to Teff MFI.
(B) Flow cytometric staining for EZH2 andH3K27me3 levels in Tregs isolated from draining lymph node (filled histograms) versus Tregs fromMC38 tumors (top) or
lung (bottom) (black lines). Data quantified as in (A).
(C) Flow cytometric staining for EZH2 levels in Teff (filled histogram) versus Treg (solid red line) cells isolated from human melanoma and blood. Relative
expression of EZH2 in Treg compared to Teff in all melanomas examined (n = 5, shown below). Two patients were treated with pembroluzimab (blue). Data
quantified as in (A).
(D) Normalized read counts of Ezh2 from RNA sequencing of Teff and Treg cells isolated from primary human colorectal carcinoma (CRC), non-small-cell lung
cancer (NSCLC), and breast cancer.
(E) Normalized read counts of Ezh2 fromRNA sequencing of Treg cells isolated from tumors of patients with CRC and patients with breast cancer versus adjacent
normal tissue.
Data represent means ± SEMs; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 from unpaired t tests. See also Figure S1.because depletion of either population permitted the outgrowth
of MC38 tumors in FP3;Ezh2fl/fl mice (Figure S2E). These data
reveal that selectively disrupting EZH2 activity in Tregs is suffi-
cient to enhance the number and function of tumor-infiltrating
effector T cells to improve tumor control.
Foxp3 Instability and Altered Function of Ezh2-Deficient
Tregs within the Tumor Microenvironment
Pharmacological inhibition of EZH2 led to a reduction of FOXP3
protein levels in Tregs (Figure 1G). Therefore, we assessed the
stability of Foxp3 expression in Tregs after genetic deletion of
Ezh2 by incorporating a Cre-activatable lineage reporter
(R26LSL-RFP) into FP3;Ezh2fl/fl mice to irreversibly mark Foxp3
expressing cells and trace Tregs that subsequently lose Foxp3
expression, defined as GFPred fluorescent protein (RFP)+ cells,
termed exFoxp3 cells (Zhou et al., 2009). As with pharmacologicinhibition of EZH2, stable Foxp3 expression was markedly
reduced with genetic deletion of Ezh2, with a greater proportion
of Tregs losing Foxp3 and becoming exFoxp3 cells (Figure 5A). In
addition, loss of Foxp3 was most prevalent in tumor tissues as
opposed to the lymphoid organs (Figure 5B). Thus, the instability
for Foxp3 in the absence of Ezh2 lowered the number of tumor-
infiltrating FOXP3+ Tregs and dramatically shifted the balance in
favor of CD8+ T cells over Tregs in tumors (Figures 5C–5E).
Ezh2-deficient TI-Tregs that retained Foxp3 expression also
exhibited a pronounced change in the profile of cytokines that
they produced. While wild-type TI-Tregs were characterized by
the production of IL-10 and minimal production of TNF-a,
Ezh2-deficient Tregs exhibited an inverse phenotype, with
increased potential to produce the pro-inflammatory cytokines
TNF-a, IFN-g, and IL-2 and reduced production of immu-
nosuppressive IL-10 (Figures 5F, 5G, and S3A). Therefore,Cell Reports 23, 3262–3274, June 12, 2018 3265
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Figure 3. EZH2 Function in TI-Tregs Is Required to Block Anti-tumor T Cell Responses
(A–C) Growth curves of multiple syngeneic tumor models—MC38 (A), TRAMPC2 (B), and B16F10 (C)—in mice with constitutive deletion of Ezh2 in Tregs
(FP3;Ezh2fl/fl) compared with littermate controls (FP3;Ezh2fl/+, Ezh2fl/[fl/+]). B16GVAX was administered 2 days before B16 tumor inoculation.
(D) Growth curves of MC38 tumors in mice with constitutive deletion of Jmjd3 in Tregs (FP3;Jmjd3fl/fl) compared with littermate controls (FP3;Jmjd3fl/+).
Inset numbers represent the number of mice that rejected tumors of total implanted pooled from all of the experiments. Data represent means ± SEMs; *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001 from two-way ANOVA with Sidak’s multiple comparisons. See also Figure S2.Ezh2-deficiency in Tregs alters TI-Tregs not only by destabilizing
Foxp3 expression, thereby reducing the frequency of suppres-
sive Tregs in tumors, but also by altering the function of
FOXP3+ Tregs, converting them from immunosuppressive to
pro-inflammatory cytokine producers specifically in tumors.
To investigate whether Ezh2 deficiency during activation was
sufficient to drive the changes in the profile of cytokines pro-
duced, we performed gene expression analysis of wild-type
Tregs compared to Ezh2-deficient Tregs that were first sorted
naive (CD62L+) and then activated by T cell receptor and
CD28 stimulation in vitro for 4 days. This analysis revealed
that early after activation, Ezh2-deficient Tregs were already
enriched in gene sets associated with TNF-a signaling and
inflammatory responses by gene set enrichment analysis
(Figure S3B). In addition, while the expression of key immu-
nosuppressive genes in Tregs Il10 and Tgfb1 was reduced,
expression of pro-inflammatory genes (e.g., Il2) exhibited
increased expression upon activation without EZH2 function
(Figure S3C). However, many other pro-inflammatory cytokines
trended toward enhanced expression in Ezh2-deficient Tregs
but were not changed significantly. Therefore, longer periods
of sustained activation within tumors or additional factors within
the tumor microenvironment must be required to stably enforce
changes in pro-inflammatory cytokine production. Collectively,
these results indicate that disrupting EZH2 activity in Tregs en-
hances anti-tumor immune responses by selectively depleting
intratumoral Tregs, altering their functionality, or a combination
of both.
Temporal Disruption of EZH2 Function in Tumor-
Bearing Mice Enhances Anti-cancer Immunity while
Minimizing Systemic Autoimmunity
In FP3;Ezh2fl/fl mice, Ezh2 is deleted in all Tregs during the initial
establishment of Foxp3 expression in the thymus. This is not
applicable to therapeutic strategies in which targeting EZH2
activity in Tregs would be limited to patients after tumors are de-
tected. Therefore, we generated mice to temporally delete Ezh2
in tumor-bearing mice using a Cre-estrogen receptor fusion pro-
tein driven by Foxp3 (FP3-ER;Ezh2fl/D) (Rubtsov et al., 2010).
Tamoxifen (tam) administration for 14 days efficiently induced
CreER activity, with 70%–90% of the in vivo-identified Tregs3266 Cell Reports 23, 3262–3274, June 12, 2018having deleted Ezh2 based on RFP reporter expression
(R26LSL-RFP) and a reduced level of H3K27me3 in RFP+ cells (Fig-
ure S4). Acute disruption of Ezh2 in Tregs by tam treatment in
FP3-ER;Ezh2fl/D mice led to significant tumor protection in the
TRAMPC2 and MC38 tumor models when performed at tumor
initiation or in established tumors (Figures 6A and S5A–S5C).
More important, in this model of prolonged tam treatment to
delete Ezh2, no symptoms of autoimmunity were observed (not
shown). This was significant, because our previous studies
showed that complete disruption of Ezh2 in Tregs leads to the
development of autoimmune symptoms in all of the tissues
examined (DuPage et al., 2015). Furthermore, when mice with
Ezh2-deficient Tregs were challenged to maintain tolerance in
adult mice (after permanent removal of wild-type Tregs), animals
succumbed to autoimmune toxicities within 3–4 weeks.
However, in that setting, Ezh2-deficient Tregs deleted Ezh2
from the time of initial expression of Foxp3, whereas here, in
this model of tam-induced deletion of Ezh2, Tregs delete Ezh2
after their development and differentiation in the presence of
EZH2. Therefore, these experiments more accurately recapitu-
late the consequences of pharmacological inhibition of EZH2
therapeutically in patients and indicate that in the setting of
blocking EZH2 function late, during Treg effector activity, auto-
immune toxicities can be prevented.
To elucidate the mechanisms driving improved tumor immu-
nity, we assessed the frequency and function of T cells shortly
after deleting Ezh2 in Tregs of mice with established tumors
(11 days of tam treatment, Figure 6B). Acute deletion of Ezh2
in Tregs increased the percentage of CD8+ T cells in tumors
but not in tumor-dLNs or lung tissues (Figure 6C). In addition,
the capacity of both CD8+ and CD4+ T cells to produce IFN-g
was enhanced selectively in both CD8+ and eCD4+ T cells infil-
trating tumors (Figures 6D, S5D, and S5E). While the effector
T cell response phenocopied the response observedwith consti-
tutive Ezh2 deletion in Tregs, this occurred without a quantitative
reduction in the frequency of TI-Tregs (Figure 6E). However,
TI-Tregs temporally deleted for Ezh2 exhibited similar changes
in the profile of cytokines produced in the constitutive Ezh2-defi-
cient Tregs, producing more TNF-a and less IL-10 (Figures 6F
and S5F). This supports the hypothesis that disruption of EZH2
function in Tregs acts predominantly by altering the function of
A C
B D
E
G
F
Figure 4. Enhanced Number and Function of
Tumor-Infiltrating T Cells with EZH2 Disrup-
tion in Tregs
(A and B) Multiplexed immunohistochemical
staining for CD8 (teal), CD4 (yellow), and Foxp3
(dark brown nuclear stain) in MC38 tumors from
control (A) or FP3;Ezh2fl/fl mice (B). Scale bars,
200 mm and 50 mm (inset).
(C and D) Percentage of CD8+ (C) or effector CD4+
T cells (eCD4+: CD4+Foxp3) (D) of viable CD45+
immune cells in tumor draining lymph node (dLN)
or tumor by flow cytometric analysis.
(E) Representative flow cytometry of IFN-g and
TNF-a produced in stimulated CD8+ T cells from
tumors in control or FP3;Ezh2fl/fl mice and quanti-
fication of results from one of two experiments.
(F) Representative flow cytometry of IFN-g and IL-2
produced in stimulated eCD4+ T cells from tumors
in control or FP3;Ezh2fl/flmice and quantification of
results from one of two experiments.
(G) Pie chart depicting the fraction of CD8+ and
eCD4+ T cells that produce multiple cytokines from
control or FP3;Ezh2fl/fl mice in (E) and (F).
Asterisks indicating significance determined by
unpaired t tests between groups are *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001. Data
represent means ± SEMs pooled from two or more
experiments; *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001 from unpaired t tests. See also
Figure S2.tumor-infiltrating FOXP3+ Tregs to promote tumor immunity. It
also indicates that the enhanced anti-tumor immune response
in FP3;Ezh2fl/fl mice is not the result of deleting Ezh2 during
thymic development of Tregs nor of FP3;Ezh2fl/fl mice being
preconditioned to reject tumors. Finally, because temporal
disruption of Ezh2 using the FP3-ER system restricts the deletion
of Ezh2 to established Tregs (Rubtsov et al., 2010), it is clear that
the effects of EZH2 disruption are mediated by alterations of
bona fide Tregs rather than T cells that transiently induce
Foxp3 expression.
The Presence of Ezh2-Deficient Tregs Potentiates Anti-
cancer Immunity
Ezh2 deficiency in TI-Tregs alters their function, but in this
setting, we also observed reductions in the frequency of intratu-
moral Tregs. To determine whether the potency of Ezh2 deletion
was partially the result of selectively eliminating Tregs from tu-
mors, we assessed the effect of Treg depletion directly, using
mice with a Foxp3-driven diphtheria toxin receptor (FP3-DTR)
(Kim et al., 2007). Administration of diphtheria toxin (7 days on,
7 days off) to FP3-DTR mice, but not tam to FP3-ER;Ezh2fl/DCell Rmice, reduced Treg frequencies systemi-
cally (Figures 7A and 7B). As a conse-
quence of complete Treg depletion using
the FP3-DTR system, mice exhibited
overt autoimmune toxicity, with pro-
nounced swelling around the eyes and
snout (Figure 7C). In addition, Treg-
depleted mice exhibited uncontrolledexpansion of CD8+ and eCD4+ T cells in lung tissue and dLNs
from tumor-bearing mice (Figure 7D). In contrast, the temporal
deletion of Ezh2 in Tregs did not generate any apparent autoim-
munity and only increased the number of CD8+ and eCD4+
T cells specifically infiltrating tumors (Figures 7C and 7D). Most
strikingly, short-term depletion of Tregs at tumor initiation did
not confer complete protective immunity because no tumors
were rejected (Figure 7E). Longer-term depletion of Tregs
beyond 7–10 days in the FP3-DTR model was not possible
because it led to fulminant and lethal autoimmune pathologies.
These results have two implications. First, it would appear that
like many immunotherapies, global Treg depletion leads to auto-
immune toxicities that will limit its use therapeutically (June et al.,
2017). Thus, because acute disruption of EZH2 in Tregs pre-
served Treg functionality in non-tumor tissues and did not
generate systemic autoimmune toxicity, it would be a more
desirable treatment. Second, temporal deletion of Ezh2 in Tregs
can confer more robust tumor protection than short-term pan
Treg depletion. This result suggests that blocking EZH2 function
in Tregs is distinct from Treg depletion when mediating
enhanced anti-tumor immunity.eports 23, 3262–3274, June 12, 2018 3267
AB
C
D
E
F
G
Figure 5. Foxp3 Instability and Altered
Function of Ezh2-Deficient Tregs within the
Tumor Microenvironment
(A) Foxp3 lineage tracing by flow cytometric anal-
ysis of the frequency of Tregs that lost Foxp3
expression (exFoxp3 cells = GFPRFP+)
compared to stable Tregs (GFP+RFP+) in an MC38
tumor from control or FP3;Ezh2fl/fl mice. Effector
CD4+Foxp3– T cells (Teff; CD4+Foxp3RFP) are
shown in gray for reference.
(B) Quantification of exFoxp3 cells in dLN and tu-
mors fromMC38 and B16F10 tumor-bearingmice.
(C) Flow cytometric analysis of the percentage of
FOXP3+ Treg cells of CD4+ T cells in an MC38
tumor from control or FP3;Ezh2fl/fl mice.
(D and E) Quantification of the percentages of
FOXP3+ Treg cells of CD4+ T cells (D) or the ratio of
CD8+ T cells to FOXP3+ Tregs (E) in dLN and tumor
from control or FP3;Ezh2fl/fl mice.
(F) Intracellular cytokine staining for IL-10, TNF-a,
IL-2, and IFN-g in FOXP3+ Treg cells isolated from
MC38 tumors of FP3;Ezh2fl/+ and FP3;Ezh2fl/fl
mice. IFN-g staining is indicated by shading. Pie
chart depicts the fraction of Tregs producing
multiple cytokines shown below. Representative
data from three mice per group and two experi-
ments.
(G) Ratio of IL-10+ Tregs to TNF-a+ Tregs isolated
from MC38 tumors in control versus FP3;Ezh2fl/fl
mice.
Data represent means ± SEMs pooled from two or
more experiments; *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001 from unpaired t tests.
See also Figure S3.To test directly whether the presence of Ezh2-deficient Tregs
directly contributes to tumor protection, we bred female mice
that harbored an FP3-DTR or an FP3-Cre knockin allele on
each X chromosome (Rubtsov et al., 2010). Because of X inacti-
vation, these female mice are naturally chimeric for two popula-
tions of Tregs: wild-type DTR+ Tregs that can be eliminated by
DT treatment and Cre+ Tregs deficient for Ezh2 that are insensi-
tive to DT-mediated depletion (Figure 7F). Using this system, we
confirmed that the continued depletion of wild-type Tregs in
chimeric females harboring residual Ezh2-deficient Tregs phe-
nocopied our results with FP3;Ezh2fl/flmice (Figure 7G). Chimeric
female mice not treated with DT did not exhibit tumor protection
in this setting, likely because the wild-type Tregs made up the
majority of Tregs-infiltrating tumors (not shown). Next, we
directly compared mice in which all Tregs were transiently3268 Cell Reports 23, 3262–3274, June 12, 2018depleted to chimeric littermates, wherein
more than half of their Tregs were tran-
siently depleted but in the context of a
remaining pool of Ezh2-deficient (or
Ezh2-sufficient) Tregs. Mice homozygous
for FP3-DTR alleles, in which all Tregs
were transiently depleted following DT
administration, never rejected their tu-
mors (Figure 7H). However, in chimeric
females in which identical conditionswere used to transiently deplete wild-type Tregs but Ezh2-defi-
cient Tregs remained, there was robust anti-tumor immunity,
with the majority of tumors being rejected (Figures 7H and S6).
These results were striking, because they definitively indicate
that the presence of Ezh2-deficient Tregs are necessary to drive
tumor protection in the context of Treg depletion, and that
disruption of EZH2 function in Tregs is more potent than Treg
depletion alone. These results are in line with the hypothesis
that Ezh2-deficient Tregs acquire a pro-inflammatory function-
ality that supports stronger tumor immunity.
DISCUSSION
Immunosuppressive Tregs are recruited to nearly all cancers,
where they can negatively affect anti-tumor immune responses.
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Figure 6. Temporal Disruption of EZH2 Function in Tregs Promotes Anti-tumor Immunity
(A) TRAMPC2 and MC38 tumor growth in FP3-ER;Ezh2fl/+ or FP3-ER;Ezh2fl/D mice treated with tam (timing indicated by shading). Inset numbers represent the
number of mice that rejected tumors of total implanted.
(B) Timeline for short-term tam administration (11 days) to FP3-ER MC38 tumor-bearing animals in (C), (D), and (E).
(C) Percentage of CD8+ T cells of CD45+ immune cells in draining lymph node (dLN), lung, and MC38 tumor tissues.
(D) Representative intracellular cytokine staining for IFN-g in CD8+ and effector CD4+ T cells in control (gray histograms) or FP3-ER;Ezh2fl/D mice (orange
histograms). Quantification of data in Figures S5D and S5E.
(E) Percentage of FOXP3+ Tregs of CD4+ T cells.
(F) Ratio of IL-10+ FOXP3+ Tregs to TNF-a+ FOXP3+ Tregs isolated from MC38 tumors in tam-treated FP3-ER;Ezh2fl/+ versus FP3-ER;Ezh2fl/D mice.
Data represent means ± SEMs from two or more experiments; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 from two-way ANOVA with Sidak’s multiple
comparisons or by unpaired t tests. See also Figures S4 and S5.Methods are needed to selectively and safely target the Tregs
that prevent anti-tumor immunity without instigating adverse
autoimmune toxicities. In this study, we investigated whether
targeting the histone H3K27 methyltransferase EZH2 in Tregs
provides a method to selectively alter TI-Tregs. We found that
Tregs infiltrating tumors exhibit increased EZH2 expression
and activity. As a consequence, we hypothesized that TI-Tregs
may be especially sensitive to EZH2 inhibition. We showed
that EZH2 activity is critical to Treg-mediated suppression of
anti-tumor immunity by genetic disruption of Ezh2 in all Tregs.
In this setting, mice were protected from multiple cancers
because of enhanced CD8+ and CD4+ T cell responses, and
this was associated with a reduced frequency and altered func-
tion of Tregs (increased pro-inflammatory cytokine production)
specifically within tumors. Temporal disruption of Ezh2 after
tumor development, which more accurately mimics therapeutic
targeting of EZH2, also led to significantly enhanced anti-tumor
T cell immunity, but affected only the function and not the num-
ber of TI-Tregs. More important, pharmacologic inhibition of
EZH2 also led to improved CD8+ T cell responses within tumors
that impeded tumor progression and was associated withreduced FOXP3 expression in Tregs. Finally, by comparing
Treg depletion in the absence or presence of Ezh2-deficient
Tregs, we showed that the presence of Ezh2-deficient Tregs
blocked tumor progression more potently than Treg depletion
alone and without the devastating autoimmunity that ensued
upon complete Treg depletion. Thus, inhibiting EZH2 activity
selectively reprograms the function of TI-Tregs without system-
ically altering Treg function, leading to enhanced tumor immunity
without autoimmune toxicity.
Targeting Tregs to enhance immune responses against cancer
has been a long-standing goal. Support for the hypothesis was
shown shortly after the initial identification of Tregs as CD25+
(IL-2Ra+) cells by anti-CD25 antibody-mediated ablation of
Tregs (Shimizu et al., 1999). While attempts to generally ablate
Tregs has shown remarkable efficacy in various preclinical tumor
models (Bos et al., 2013; Simpson et al., 2013; Teng et al.,
2010b), clinical efficacy in cancer trials has been discouraging
(Liu et al., 2016a; Rech et al., 2012). This is partly because of a
lack of targets that provide sufficient specificity for Tregs. Even
the prototypical target—the IL-2/IL-2R pathway—is problematic
because this pathway also is important for promoting effectorCell Reports 23, 3262–3274, June 12, 2018 3269
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Figure 7. The Presence of Ezh2-Deficient Tregs Are Required to Promote Tumor Rejection
(A) Timeline for diphtheria toxin (DT) administration to FP3-DTR mice or tam administration to FP3-ER mice bearing MC38 tumors in (B), (C), and (D).
(B) Percentage of FOXP3+ Tregs of CD4+ T cells in lymph nodes.
(C) Representative pictures of mice temporally disrupted for EZH2 in Tregs (left) or depleted of Tregs (right).
(D) Absolute number of CD8+ T cells (top) and effector CD4+ T cells (eCD4+: CD4+Foxp3, bottom) in tumor, lung, and draining lymph node (dLN) of indicated
mice.
(E) TRAMPC2 and MC38 tumor growth in FP3-DTRmice with or without DT treatment (time of administration indicated by shading). Inset numbers represent the
number of mice that rejected tumors of total implanted.
(F) Scheme (top) and representative flow cytometry plot (bottom) illustrating chimeric female model for transiently eliminating wild-type Tregs in the presence of
Ezh2-deficient Tregs.
(G) MC38 tumor growth in indicated chimeric female mice treated with diphtheria toxin from tumor inoculation throughout.
(H) MC38 tumor growth in indicated chimeric female mice or FP3-DTR/FP3-DTR mice treated short term with diphtheria toxin from days 2 to 4 after tumor
inoculation. Inset numbers represent the number of mice that rejected tumors of total inoculated in one of two experiments (see Figure S6 for cumulative results).
p values indicate comparison between red (Ezh2fl/fl) and blue (FP3-DTR) lines, but comparison of red to black (Ezh2fl/+) lines at these three time points also was
significant. No significant difference at any time point observed between black and blue lines.
Data represent means ± SEMs from two or more experiments; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 from two-way ANOVA with Sidak’s multiple
comparisons or by unpaired t tests. See also Figure S6.T cell responses that can act against tumors (Curiel, 2007).
Furthermore, while attempts to ablate Tregs in patients have
yet to exhibit significant toxicity, the potential to drive dangerous
systemic inflammation is a major concern (Joshi et al., 2015; Liu3270 Cell Reports 23, 3262–3274, June 12, 2018et al., 2016a). Therefore, methods to selectively deplete the
Tregs suppressing anti-tumor immune responses are essential.
It is important to note that when Tregs have been specifically
depleted within tumors, it appears to be sufficient to liberate
productive anti-tumor immune responses in preclinical models
of cancer (Chen et al., 2007). Antibodies directed toward
CTLA-4 in murine cancer models have been demonstrated to
deplete predominantly intratumoral Tregs leading to improved
anti-tumor immunity (Selby et al., 2013; Simpson et al., 2013;
Sugiyama et al., 2013). However, in patients receiving clinically
approved anti-CTLA-4 agents, this mechanism has not been
consistently demonstrated (Liu et al., 2016a; Tanaka and Saka-
guchi, 2017). The selectivity of anti-CTLA-4 for intratumoral
Tregs has been attributed to the antibodies’ preferential binding
of the most activated Tregs, which are known to have the great-
est levels of surface-exposed CTLA-4.
In this study, we found that constitutive disruption of EZH2 in
Tregs leads to dramatic reductions in intratumoral Treg fre-
quencies without disrupting the frequency of Tregs in lymphoid
and non-tumor tissues. This is likely because of the decreased
stability of Foxp3 expression in highly activated Tregs that lack
functional EZH2 (DuPage et al., 2015). EZH2 is induced upon
activation via the T cell receptor and CD28; thus, intratumoral
Tregs likely have a particularly strong dependence on EZH2
activity. It is noteworthy that by targeting other pathways that
are induced in activated Tregs, a similar selectivity for disrupting
intratumoral Treg stability and function has been observed (Liu
et al., 2016a; Luo et al., 2016). Recently, blockade of the nuclear
factor kB (NF-kB) pathway in Tregs was shown to selectively
disrupt the activity of intratumoral Tregs and promote stronger
anti-tumor immune responses (Grinberg-Bleyer et al., 2017).
The NF-kB pathway directly regulates the activation of Ezh2
expression (Neo et al., 2014), potentially connecting our studies
and providing strong support for a general methodology to target
intratumoral Tregs based on their highly activated state in tumor
tissues.
Short-term disruption of EZH2 activity in Tregs by pharmaco-
logical inhibition or temporal genetic deletion also led to
enhanced anti-tumor CD8+ T cell responses. However, this
occurred without significant reductions in the intratumoral fre-
quency of Tregs, but it was associated with the rapid acquisition
of an immunostimulatory cytokine profile in tumor-infiltrating
FOXP3+ Tregs. Our study provides further support for a shifting
paradigm for disabling Tregs in cancer by altering their function-
ality. This approach is superior to Treg depletion because, as we
and others have demonstrated, Treg ablation drastically disrupts
immune homeostasis and can lead to irreversible autoimmunity.
By instead tapping into pathways that control the natural
context-specific plasticity of Tregs, it is possible that we can
reprogram the functionality of Tregs with great anatomical and
context specificity that only narrowly disrupts immunoregulation
without causing systemic autoimmune toxicity (DuPage and
Bluestone, 2016). In the context of cancer, mechanisms to
induce Foxp3 instability and alter Treg function have been
demonstrated by targeting the critical Treg receptors, such as
CD25, GITR, and Nrp-1 (Nakagawa et al., 2016; Overacre-Del-
goffe et al., 2017; Rech et al., 2012; Schaer et al., 2013). Admin-
istration of blocking antibodies against these receptors or
genetic disruption of the pathways activated downstream of
them has been shown to destabilize Foxp3 expression and drive
the production of IFN-g in Tregs isolated from tumor tissues.
Treg reprogramming toward pro-inflammatory activities hasbeen shown to be critical for the efficacy of anti-tumor immune
responses and boosting immunotherapy in preclinical models
(Sharma et al., 2010). However, few studies have demonstrated
Treg reprogramming with small-molecule drugs that target the
downstream pathways that these receptors engage. Epigenetic
regulators that control chromatin states, such as EZH2, may be
ideal targets for reprogramming Treg function (Liu et al., 2013).
Targeting EZH2 is significant because inhibitors of EZH2 are be-
ing evaluated in clinical trials as direct anti-cancer agents in
which EZH2 is predicted to have tumor-promoting oncogenic
activity, especially in cancers harboring gain-of-function muta-
tions in EZH2 such as melanomas, diffuse large-cell B cell
lymphomas, and follicular lymphomas (Kim and Roberts,
2016). Moreover, EZH2 has been shown to regulate chemokine
production within cancer cells, shaping their immune microenvi-
ronment and making it more permissive to cancer progression
(Nagarsheth et al., 2016; Peng et al., 2015). Among the myriad
of pleiotropic effects induced by EZH2 inhibition that have
been described, we have revealed here an additional activity of
EZH2 in activated TI-Tregs that, if disrupted, synergizes with
cancer immunotherapeutic strategies.
Finally, we identified EZH2 because of its CD28-dependent
induction. Therefore, EZH2 regulation is likely to be critical for
immune checkpoint blockade therapies that target the CD28
pathway such as anti-CTLA-4 and anti-programmed cell death
protein-1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies
(Hui et al., 2017; Kamphorst et al., 2017; Leach et al., 1996).
Checkpoint blockade antibodies, by enhancing CD28 signaling,
may induce EZH2 in Tregs, thereby enhancing immunosuppres-
sion in tumors and resistance to checkpoint blockade immuno-
therapy. In this setting, the inhibition of EZH2 function may
reverse this effect and strengthen the efficacy of these therapies.
Furthermore, because preexisting immune infiltration into
tumors is a strong indicator of responsiveness to checkpoint
blockade, the capacity for EZH2 inhibition to increase the infiltra-
tion of CD8+ T cells in tumors also may augment the effective-
ness of these therapies (Tumeh et al., 2014; Vonderheide et al.,
2017). In conclusion, we demonstrate that the blockade of
EZH2 function in Tregs can selectively break tolerance in
the tumor microenvironment without unleashing systemic
autoimmune toxicities, revealing that context-specific activ-
ities of epigenetic enzymes may be targeted for cancer
immunotherapies.
EXPERIMENTAL PROCEDURES
Mice
All of the mice used were bred onto a C57BL/6 background for a minimum of
five generations. All of the mouse experiments (or cells from mice of given ge-
notypes) used comparisons between littermates or age-matched control mice.
Foxp3-GFP-hCre transgenic, Foxp3YFP-cre knockin, and Foxp3EGFP-cre-ERT2
mice express Cre recombinase in FOXP3+ cells using distinct technologies
(Rubtsov et al., 2008, 2010; Zhou et al., 2008). Ezh2fl mice harbor loxP sites
flanking exons 16–19 encoding the SET domain (Su et al., 2003). For tam treat-
ments, mice were treated by oral gavage with a dose of 160 mg/kg suspended
in corn oil two times per week. For diphtheria toxin treatments, Foxp3DTRmice
were treated as indicated with a dose of 0.04mg/kg up to three times per week
every other day (Kim et al., 2007). For tumor studies, syngeneic C57BL/6 mice
were inoculated with 13 105 MC38 cells engineered to express luciferase and
GFP, 1 3 106 TRAMPC2 cells (all in male mice), or 1 3 104 B16F10 cellsCell Reports 23, 3262–3274, June 12, 2018 3271
expressing GFP in 100 mL of PBS in the flank. Vaccination studies with B16-
GVAX (GM-CSF expressing B16 cells) were performed with 13 106 irradiated
cells (50 Gy) injected subcutaneously in the flank 2 days before inoculating
13 105 B16F10 cells. For Ezh2 inhibitor studies, mice were treated twice daily
by oral gavage with 300mg/kg CPI-1205made in a vehicle of 0.5%methyl cel-
lulose and 0.2% Tween 80. The treatment regimen began 1 day after tumor
inoculation and continued throughout the course of the experiment. Tumor
measurements were performed by a single operator in three dimensions using
calipers two or more times per week. All of the experiments were conducted
according to the Institutional Animal Care and Use Committee guidelines of
the University of California, San Francisco.
Murine Lymphocyte Isolation
Resected tumors and lung tissues were minced to 1 mm3 fragments and
digested in RPMI media supplemented with 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES), 20 mg/mL DNase I (Roche), and 125 U/mL
collagenase D (Roche) using a gentleMACS tissue dissociator (Miltenyi) for
45 min at 37C. Cells from lymphoid organs were prepared by mechanical
disruption between frosted slides. All of the suspensions were passaged over
40 mm filters before cell staining or in vitro stimulation. Cytokine staining was
performed with 3 3 106 cells after 210 min of in vitro stimulation in Opti-MEM
media with Brefeldin A (eBioscience), phorbol 12-myristate 13-acetate (PMA)
(Sigma), and ionomycin (Sigma). Fixation and permeabilization of cells were
conducted for intracellular staining using BD Cytofix/Cytoperm (BD Biosci-
ences) for cytokines or the eBioscience Foxp3 fixation/permeabilization kit
(ThermoFisher).
Human Lymphocyte Isolation
For human melanomas, freshly isolated samples were minced and digested
overnight with a buffer consisting of collagenase type 4 (4188; Worthington
Biochemical), DNase (SDN25-1G; Sigma-Aldrich), 10% fetal bovine serum
(FBS), 1%HEPES, and 1%penicillin in RPMImedium. Single-cell suspensions
were double filtered, centrifuged, and counted. Biopsies of melanoma tumors
were performed after patients provided informed consent under the University
of California, San Francisco (UCSF) Committee on Human Research Protocol
138510.
FlowCytometry
Surface marker stains for murine samples were carried out with BV605-con-
jugated anti-mouse CD4 (RM4-5, BioLegend), allophycocyanin (APC)-Cy7-
conjugated anti-mouse CD8a (53-6.7, BD Biosciences), phycoerythrin
(PE)-Cy7-conjugated anti-mouse PD1 (RMP1-30, BioLegend), BUV395-con-
jugated anti-mouse CD45 (30-F11, BD Biosciences), and LIVE/DEAD
Fixable Blue Dead Cell Stain (Invitrogen). Intracellular staining of cells was
accomplished with fluorescein isothiocyanate (FITC)-conjugated anti-
mouse Foxp3 (FJK-16 s, eBioscience), PerCP-Cy5.5-conjugated anti-
mouse TNF-a (MP6-XT22, BioLegend), eFluor450-conjugated anti-mouse
IFN-g (XMG1.2, eBioscience), APC-conjugated anti-mouse IL-10 (JES5-
16E3, eBioscience), and BV711-conjugated anti-mouse IL-2 (JES6-5H4,
BioLegend). Antibodies against H3K27me3 (C36B11, Cell Signaling Tech-
nology) and total H3 (D1H2, Cell Signaling Technology) were used after
1.6% formalin fixation and methanol (50%) permeabilization. For human
samples, all of the antibodies used for staining were from eBioscience
unless otherwise stated: anti-CD3 (UCHT1), anti-hCD8 (RPA-T8), anti-
hCD45 (HI30), anti-CD4 (SK3), anti-FOXP3 (PCH101), anti-hCTLA-4
(14D3), anti-PD-1 (EH12.2H7, BioLegend), anti-EZH2 (D2C9, Cell Signaling
Technology), and LIVE/DEAD Fixable Aqua Dead Cell Stain (Life Technolo-
gies, Thermo Fisher Scientific). Flow cytometry was performed on an LSR II
or LSRFortessa (BD Biosciences), and datasets were analyzed using FlowJo
software (Tree Star).
Histology
Tissues fixed in 10% formalin for 24 hr, preserved in 70% ethanol, and
embedded in paraffin were cut and sections stained with H&E. Chromogenic
multiplex immunohistochemistry was performed with anti-CD4 (EPR19514,
Abcam) at 1:1,000 dilution, anti-CD8a (4SM15, eBioscience) at 1:50 dilution,
and anti-FoxP3 (FJK-16 s, eBioscience) at 1:50 dilution.3272 Cell Reports 23, 3262–3274, June 12, 2018Statistical Methods
p values were obtained from unpaired two-tailed Student’s t tests for all of the
statistical comparisons between two groups, and data were displayed as
means ± SEMs. For tumor growth curves, two-way ANOVA was used with
Sidak’s multiple comparisons test performed at each time point. p values
are denoted in the figures by *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001.
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